This English translation is AI-generated and provided for reference only.
中國社會

Navigating Tensions in China's Centralized Drug Procurement

Amidst public concerns over drug efficacy, China's healthcare system faces scrutiny as doctors and regulatory bodies clash over centralized procurement practices. The debate highlights inherent tensions between cost control and quality assurance, underscoring the need for balanced oversight in healthcare policy.

In response to claims that drugs from centralized procurement are ineffective, such as "blood pressure not lowering" and "anesthetics not working," the National Healthcare Security Administration recently issued a new statement. While it's good to have a response, this one came too quickly and doesn't match the amount of work required. Moreover, it lacks traceable, real-name endorsements, and even the journalist conducting the interview wasn't named. Therefore, further responses to public concerns are indeed necessary.

During the Shanghai Two Sessions, Zheng Minhua, a standing committee member of the Shanghai CPPCC and director of the General Surgery Department at Ruijin Hospital, pointed out in a media interview that while the national drug procurement has achieved significant results, the public, hospitals, and doctors have other feelings. This led to the widely circulated saying, "blood pressure not lowering, anesthetics not working, laxatives not effective." In fact, there are many posts online about the quality of drugs and medical devices, and these are not isolated opinions.

Zheng Minhua, along with 20 Shanghai CPPCC members, jointly submitted a proposal to the Shanghai CPPCC titled "How to Use Effective Drugs in the Context of Centralized Drug Procurement."

您已閱讀13%(1283字),剩餘87%(8476字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×